Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy

JNCI Cancer Spectrum(2024)10.1093/jncics/pkae067Source: DataRank Database

Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy is a research paper published in JNCI Cancer Spectrum (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.28)OA: goldTopics (46)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Jessica B. Long,Sarah J. Westvold ORCID,Khushi Agnish,Hannah D. McManus ORCID,Michael Leapman ORCID

Live enrichment

PubMed:39133171 PMC:PMC11376369 OpenAlex:https://openalex.org/W4401526009

NCI NIH HHS

Grant: R01 CA226842

National Institutes of Health

Grant: R01 CA226842-01A1

NCATS NIH HHS

Grant: UL1 TR001863

National Institutes of Health

Grant: 3R01CA226842-02S1

Investigation of the bidirectional relationship between kidney cancer treatment and dementia

National Cancer Institute

FWCI

0.28

Citation Percentile

0.6%

Citation Trend

2025

goldLicense: cc-by

journalhttps://academic.oup.com/jncics/article-pdf/8/5/pkae067/60568975/pkae067.pdf

journalhttps://doi.org/10.1093/jncics/pkae067

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39133171

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11376369

Europe_PMChttps://europepmc.org/articles/PMC11376369

Fields of Study

Renal cell carcinoma treatmentEconomic and Financial Impacts of CancerCancer Immunotherapy and Biomarkers03 medical and health sciences0302 clinical medicine

MeSH Terms

Assessment of Medication AdherenceAdministration, OralAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Renal CellHealth ExpendituresFemaleMedicareHumansImmunotherapyKidney NeoplasmsMaleRetrospective StudiesUnited StatesDrug MonitoringFee-for-Service PlansMedication Adherence

Keywords

MedicineRenal cell carcinomaImmunotherapyOncologyCarcinomaInternal medicineCancerMaleAged, 80 and overAdministration, OralAntineoplastic AgentsFee-for-Service PlansMedicareArticleKidney NeoplasmsUnited StatesHumansFemaleHealth ExpendituresDrug MonitoringCarcinoma, Renal CellRetrospective StudiesAged

Sustainable Development Goals

SDG 0: Good health and well-being

Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy

FAIR Checklist

Authors (11)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)